New biosimilar aims to rival cosentyx for psoriasis
NCT ID NCT06630559
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether CT-P55, a biosimilar of secukinumab, works as well as the approved drug Cosentyx for moderate to severe plaque psoriasis. 153 adults with chronic psoriasis for at least 6 months are receiving either CT-P55 or Cosentyx injections. The main goal is to see how much their psoriasis improves over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT-P55 (a biosimilar of secukinumab)
What this could lead to
If it works, this could provide a more affordable treatment option for people with moderate to severe plaque psoriasis.
What could go wrong
This is a biosimilar, so it may not be as effective or safe as the original drug. The trial is relatively small (153 people) and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rheumatology Clinic NZOZ Lecznica MAK-MED s.c.
Nadarzyn, Poland